Author pages are created from data sourced from our academic publisher partnerships and public sources.
Share This Author
Linearized hepatitis B surface antigen and hepatitis B core-related antigen in the natural history of chronic hepatitis B.
HQ-HBsAg and HBcrAg showed unique patterns of distribution throughout the five disease phases of CHB, including high detectability rates after HBsAg seroclearance, opening up different possibilities for their applicability.
Role of IL28B and inosine triphosphatase polymorphisms in the treatment of chronic hepatitis C virus genotype 6 infection
In chronic HCV genotype 6 infection, IL28B polymorphisms were associated with response to therapy and ITPA polymorphisms influenced the degree of anaemia but not thrombocytopenia during therapy.
Review article: hepatitis B core‐related antigen (HBcrAg): an emerging marker for chronic hepatitis B virus infection
- L. Mak, D. Wong, K. Cheung, W. Seto, Clinton Lai, M. Yuen
- Biology, MedicineAlimentary pharmacology & therapeutics
- 1 January 2018
Serological markers can be non‐invasive alternatives to reflect intrahepatic viral replicative activity in chronic hepatitis B and be advocated as a novel serum marker for disease monitoring and prognostication of CHB.
Detection of Colorectal Adenoma by Narrow Band Imaging (HQ190) vs. High-Definition White Light Colonoscopy: A Randomized Controlled Trial
190-NBI colonoscopy was superior to the conventional HD-WL in detecting colorectal adenomas or polyps, but there was no significant difference in adenoma miss rates.
Body‐mass index is associated with fibrosis regression during long‐term nucleoside analogue therapy in chronic hepatitis B
Factors influencing changes in liver stiffness measurements during long‐term nucleoside analogue therapy for chronic hepatitis B (CHB) have not been thoroughly investigated.
Inverse relationship between hepatic steatosis and hepatitis B viremia: Results of a large case‐control study
It is concluded that severe steatosis was associated with increased fibrosis in CHB patients and was independently associated with lower serum HBV DNA levels, suggesting its potential negative effects on viral replication.
Review article: long‐term safety of oral anti‐viral treatment for chronic hepatitis B
- G. Wong, W. Seto, V. Wong, M. Yuen, H. Chan
- Medicine, BiologyAlimentary pharmacology & therapeutics
- 1 March 2018
Safety profile of nucleos(t)ide analogues is an important issue in view of its widespread use for decades in patients with chronic hepatitis B (CHB).
Prognostic significance of liver stiffness for hepatocellular carcinoma and mortality in HBeAg‐negative chronic hepatitis B
- J. Fung, Clinton Lai, W. Seto, D. Wong, M. Yuen
- Biology, MedicineJournal of viral hepatitis
- 1 October 2011
In HBeAg‐negative CHB patients, a liver stiffness measurement of ≥10 kPa was associated with a significantly increased risk of subsequent HCC development and mortality, and after multivariate analysis, only Liver stiffness measurement (LSM) was significantly associated with HCCdevelopment and mortality.
Relationship between HBsAg, HBcrAg and hepatocellular carcinoma in patients with undetectable HBV DNA under nucleos(t)ide therapy
- K. Cheung, W. Seto, D. Wong, Clinton Lai, M. Yuen
- Medicine, BiologyJournal of viral hepatitis
- 1 August 2017
A higher pre‐ and post‐NA treatment HBcrAg level (but not HBsAg) was associated with an increased risk of HCC development in patients achieving undetectable serum HBV DNA while on NA therapy, and may serve as a novel risk marker for HCC in this group of patients.